Recognition for inventors in the fight against disease
[Date: ]

The fight against leukaemia and malaria - two of the world's most virulent diseases - was rewarded in two out of the four categories at the recent European Inventor of the Year awards.

NICE opens NHS door to blood cancer therapy Revlimid
27 April 2009
It was further good news for patients with multiple myeloma in the UK last week after the National Institute for Health and Clinical Excellence cemented its position on using Celgene’s Revlimid to treat the disease.

ChemGenex statement.

A trial of omacetaxine for chronic myeloid leukaemia in people who cannot take tyrosine kinase inhibitors (TKIs) or whose leukaemia has not responded to TKIs
This trial is looking at a drug called omacetaxine (OM) for chronic myeloid leukaemia in people who have not responded to treatment with tyrosine kinase inhibitors.

Guidance on NHS patients who wish to pay for additional private care:
Executive summary
The key points which NHS organisations should take from this guidance are:
• NHS organisations should not withdraw NHS care simply because a patient chooses to buy additional private care.

<h2>View the full article article as a <a href="http://www.cmlsupport.org.uk/files/Yours_Magazine59_Ros_Shirran_p38.jpg"... or download it as a <a href="http://www.cmlsupport.org.uk/files/YOUR059-38_I_beat_it.pdf">PDF</a> file.</h2>

Dear RCF supporter,

We are hoping that volunteers with rarer cancers will be able to help us collect information about the process of diagnosis at GP level for people with rarer cancers. The aim of the project is to improve the diagnosis of rarer cancers and so help improve outcomes. Patients will need to ask their GP practice for access to their medical records and then use the attached data collection form to extract the information. The findings will be anonymised and written up in a report for the Department of Health. You will find more information about the project in the attached briefing notes.

UK cancer specialists “not telling patients about new drugs”
26 August 2008
A quarter of doctors specialising in the cancer myeloma have admitted not telling their patients about expensive new drugs which have yet to be appraised by the National Institute for Health and Clinical Excellence, and nearly all of them said this was because they feared that doing so might “distress, upset or confuse” the patients.

http://leukaemialymphomaresearch.org.uk/information/download-our-patient...

'Europe’s rare cancer
community calls for
a more radical approach'



Anna Wagstaff




The genomic era offers enormous potential for patients with rare cancers, but progress is being
held back by structures that separate research from care, regulatory practices that penalise
small patient populations, and rules that restrict close working between researchers,
companies, patients and regulators.